NQO1 C609T polymorphism and esophageal cancer risk: A HuGE review and meta-analysis

BMC Medical Genetics

Volumn 14, Issue 1, 2013, Pages

  Yanling, Hu ^a   Yuhong, Zhang ^a   Wenwu, He ^a,b   Lei, Xian ^a   Mingwu, Chen ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b AFFILIATED HOSPITAL OF NORTH SICHUAN MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELE; ARTICLE; CANCER RISK; CASE CONTROL STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HUMAN; PUBLISHING;

CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); POLYMORPHISM, GENETIC;

EID: 84874479030     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-14-31     Document Type: Article

References (34)

1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003, 349(23):2241-2252. 10.1056/NEJMra035010, 14657432.
2. Nebert DW, Roe AL, Vandale SE, Bingham E, Oakley GG. NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet Med 2002, 4(2):62-70. 10.1097/00125817-200203000-00003, 11882782.
3. Larson RA, Wang Y, Banerjee M, Wiemels J, Hartford C, Le Beau MM, Smith MT. Prevalence of the inactivating 609C→T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 1999, 94(2):803-807.
4. Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, Ross D. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H: quinone oxidoreductase 1. Mol Pharmacol 2001, 59(2):263-268.
5. Kuehl BL, Paterson JW, Peacock JW, Paterson MC, Rauth AM. Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer 1995, 72(3):555-561. 10.1038/bjc.1995.373, 2033894, 7669561.
6. Moran JL, Siegel D, Ross D. A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H:quinone oxidoreductase 1 (NQO1) to benzene toxicity. Proc Natl Acad Sci USA 1999, 96(14):8150-8155. 10.1073/pnas.96.14.8150, 22203, 10393963.
7. Smith MT. Benzene, NQO1, and genetic susceptibility to cancer. Proc Natl Acad Sci USA 1999, 96(14):7624-7626. 10.1073/pnas.96.14.7624, 33590, 10393869.
8. Schulz WA, Krummeck A, Rosinger I, Eickelmann P, Neuhaus C, Ebert T, Schmitz-Drager BJ, Sies H. Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics 1997, 7(3):235-239. 10.1097/00008571-199706000-00008, 9241663.
9. Chen H, Lum A, Seifried A, Wilkens LR, Le Marchand L. Association of the NAD(P)H:quinone oxidoreductase 609C→T polymorphism with a decreased lung cancer risk. Cancer Res 1999, 59(13):3045-3048.
10. Xu LL, Wain JC, Miller DP, Thurston SW, Su L, Lynch TJ, Christiani DC. The NAD(P)H:quinone oxidoreductase 1 gene polymorphism and lung cancer: differential susceptibility based on smoking behavior. Cancer Epidemiol Biomarkers Prev 2001, 10(4):303-309.
11. Radjendirane V, Joseph P, Lee YH, Kimura S, Klein-Szanto AJ, Gonzalez FJ, Jaiswal AK. Disruption of the DT diaphorase (NQO1) gene in mice leads to increased menadione toxicity. J Biol Chem 1998, 273(13):7382-7389. 10.1074/jbc.273.13.7382, 9516435.
12. Klaidman LK, Leung AC, Adams JD. High-performance liquid chromatography analysis of oxidized and reduced pyridine dinucleotides in specific brain regions. Anal Biochem 1995, 228(2):312-317. 10.1006/abio.1995.1356, 8572312.
13. Long DJ, Gaikwad A, Multani A, Pathak S, Montgomery CA, Gonzalez FJ, Jaiswal AK. Disruption of the NAD(P)H:quinone oxidoreductase 1 (NQO1) gene in mice causes myelogenous hyperplasia. Cancer Res 2002, 62(11):3030-3036.
14. Sameer AS, Shah ZA, Syeed N, Rasool R, Afroze D, Siddiqi MA. NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and colorectal cancer predisposition in the ethnic Kashmiri population. Asian Pac j cancer prev: APJCP 2010, 11(1):209-213.
15. Cho CG, Lee SK, Nam SY, Lee MS, Lee SW, Choi EK, Park HJ, Kim SY. Association of the GSTP1 and NQO1 polymorphisms and head and neck squamous cell carcinoma risk. J Korean Med Sci 2006, 21(6):1075-1079. 10.3346/jkms.2006.21.6.1075, 2721932, 17179690.
16. Ioannidis JP, Ntzani EE, Trikalinos TA. 'Racial' differences in genetic effects for complex diseases. Nat Genet 2004, 36(12):1312-1318. 10.1038/ng1474, 15543147.
17. Thakkinstian A, McElduff P, D'Este C, Duffy D, Attia J. A method for meta-analysis of molecular association studies. Stat Med 2005, 24(9):1291-1306. 10.1002/sim.2010, 15568190.
18. Thakkinstian A, McEvoy M, Minelli C, Gibson P, Hancox B, Duffy D, Thompson J, Hall I, Kaufman J, Leung TF. Systematic review and meta-analysis of the association between {beta}2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol 2005, 162(3):201-211. 10.1093/aje/kwi184, 15987731.
19. Petiti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis 1994, Oxford: Oxford University Press.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-560. 10.1136/bmj.327.7414.557, 192859, 12958120.
21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634. 10.1136/bmj.315.7109.629, 2127453, 9310563.
22. Li Y, Zhang JH, Guo W, Wang R, Wen DG, Wei LZ. Polymorphism of NAD(P)H dehydrogenase (quinone) 1 (NQO1) C 609 T and risk of esophageal neoplasm. Zhonghua Liu Xing Bing Xue Za Zhi 2004, 25(8):731.
23. Zhang JH, Li Y, Wang R, Sarbia M, Guo W, Wen DG, Wei LZ, Chen ZF, Kuang G, Zhang LW. The NAD(P)H: quinone oxidoreductase 1 C609T polymorphism and susceptibility to esophageal cancer. Zhonghua Xue Yi Chuan Xue Za Zhi 2003, 20(6):544-546.
24. di Martino E, Hardie LJ, Wild CP, Gong YY, Olliver JR, Gough MD, Bird NC. The NAD(P)H:quinone oxidoreductase I C609T polymorphism modifies the risk of Barrett esophagus and esophageal adenocarcinoma. Genet Med 2007, 9(6):341-347. 10.1097/GIM.0b013e3180654ccd, 17575500.
25. Hamajima N, Matsuo K, Iwata H, Shinoda M, Yamamura Y, Kato T, Hatooka S, Mitsudomi T, Suyama M, Kagami Y. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol 2002, 7(2):103-108.
26. Marjani HA, Biramijamal F, Rakhshani N, Hossein-Nezhad A, Malekzadeh R. Investigation of NQO1 genetic polymorphism, NQO1 gene expression and PAH-DNA adducts in ESCC. A case-control study from Iran Genet Mol Res 2010, 9(1):239-249.
27. Sarbia M, Bitzer M, Siegel D, Ross D, Schulz WA, Zotz RB, Kiel S, Geddert H, Kandemir Y, Walter A. Association between NAD(P)H: quinone oxidoreductase 1 (NQ01) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract. Int J Cancer 2003, 107(3):381-386. 10.1002/ijc.11430, 14506737.
28. von Rahden BH, Stein HJ, Langer R, von Weyhern CW, Schenk E, Doring C, Siewert JR, Hofler H, Sarbia M. C609T polymorphism of the NAD(P)H:quinone oxidoreductase I gene does not significantly affect susceptibility for esophageal adenocarcinoma. Int J Cancer 2005, 113(3):506-508. 10.1002/ijc.20576, 15455349.
29. Zhang J, Schulz WA, Li Y, Wang R, Zotz R, Wen D, Siegel D, Ross D, Gabbert HE, Sarbia M. Association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism with esophageal squamous cell carcinoma in a German Caucasian and a northern Chinese population. Carcinogenesis 2003, 24(5):905-909. 10.1093/carcin/bgg019, 12771035.
30. Zhang JH, Li Y, Wang R, Geddert H, Guo W, Wen DG, Chen ZF, Wei LZ, Kuang G, He M. NQO1 C609T polymorphism associated with esophageal cancer and gastric cardiac carcinoma in North China. World J Gastroenterol 2003, 9(7):1390-1393.
31. Zhang WC, Yin LH, Pu YP, Liang GY, Hu X, Liu YZ, Cui YS. Relationship between quinone oxidoreductase1 gene ns-cSNP and genetic susceptibility of esophageal cancer. Zhonghua Yu Fang Yi Xue Za Zhi 2006, 40(5):324-327.
32. Traver RD, Horikoshi T, Danenberg KD, Stadlbauer TH, Danenberg PV, Ross D, Gibson NW. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 1992, 52(4):797-802.
33. Rauth AM, Goldberg Z, Misra V. DT-diaphorase: possible roles in cancer chemotherapy and carcinogenesis. Oncol Res 1997, 9(6-7):339-349.
34. Wang Z, Hu J, Zhong J. Meta-analysis of the NAD(P)H: quinine oxidoreductase 1 gene 609 C > T polymorphism with esophageal cancer risk. DNA Cell Biol 2012, 31(4):560-567. 10.1089/dna.2011.1332, 22017531.